Gyre Therapeutics, Inc. (NASDAQ:GYRE – Get Free Report) shares traded up 8.2% on Monday . The company traded as high as $11.82 and last traded at $11.78. 19,577 shares traded hands during mid-day trading, a decline of 74% from the average session volume of 74,201 shares. The stock had previously closed at $10.89.
Gyre Therapeutics Stock Up 2.0 %
The business’s 50 day moving average price is $12.19 and its two-hundred day moving average price is $14.37.
Insider Activity
In other news, Director Nassim Usman sold 3,452 shares of the firm’s stock in a transaction that occurred on Friday, June 28th. The shares were sold at an average price of $12.00, for a total value of $41,424.00. Following the sale, the director now directly owns 1,636 shares in the company, valued at approximately $19,632. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 2.92% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Gyre Therapeutics
About Gyre Therapeutics
Gyre Therapeutics, Inc, a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases.
Read More
- Five stocks we like better than Gyre Therapeutics
- Transportation Stocks Investing
- Target Hits the Mark: Q2 Earnings Exceed Expectations
- How to Capture the Benefits of Dividend Increases
- Is Tesla’s Rebound Just Starting? Why You Should Consider Buying
- Conference Calls and Individual Investors
- Stanley Druckenmiller’s Latest Bet: MELI—Should You Follow Suit?
Receive News & Ratings for Gyre Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gyre Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.